Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2017 1
2018 4
2019 3
2020 3
2021 2
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean vela d (131 results)?
Microfluidics-free single-cell genomics with templated emulsification.
Clark IC, Fontanez KM, Meltzer RH, Xue Y, Hayford C, May-Zhang A, D'Amato C, Osman A, Zhang JQ, Hettige P, Ishibashi JSA, Delley CL, Weisgerber DW, Replogle JM, Jost M, Phong KT, Kennedy VE, Peretz CAC, Kim EA, Song S, Karlon W, Weissman JS, Smith CC, Gartner ZJ, Abate AR. Clark IC, et al. Nat Biotechnol. 2023 Nov;41(11):1557-1566. doi: 10.1038/s41587-023-01685-z. Epub 2023 Mar 6. Nat Biotechnol. 2023. PMID: 36879006 Free PMC article.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Coleman RL, et al. N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562800 Free PMC article. Clinical Trial.
The independent value of adding veliparib during induction therapy without veliparib maintenance was less clear. (Funded by AbbVie; VELIA/GOG-3005 ClinicalTrials.gov number, NCT02470585.)....
The independent value of adding veliparib during induction therapy without veliparib maintenance was less clear. (Funded by AbbVie; VELIA …
Ploidy and Number of Chromosomes in the Alveolate Alga Chromera velia.
Vazač J, Füssy Z, Hladová I, Killi S, Oborník M. Vazač J, et al. Protist. 2018 Feb;169(1):53-63. doi: 10.1016/j.protis.2017.12.001. Epub 2017 Dec 18. Protist. 2018. PMID: 29367153
Chromera velia is an alveolate alga which represents the closest known phototrophic relative to apicomplexan parasites. ...Probes were derived from three single copy genes coding for 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) kinase, 2-C-methyl-D-ery …
Chromera velia is an alveolate alga which represents the closest known phototrophic relative to apicomplexan parasites. ...Probes wer …
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM. You B, et al. J Clin Oncol. 2023 Jan 1;41(1):107-116. doi: 10.1200/JCO.22.00430. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867965 Free PMC article.
PURPOSE: In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associated with improved progression-free survival (PFS) compared with carboplatin-paclitaxel alone in patients with high-grade ovarian carcinomas. . …
PURPOSE: In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associate …
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.
Mizuno M, Ito K, Nakai H, Kato H, Kamiura S, Ushijima K, Nagao S, Takano H, Okadome M, Takekuma M, Tokunaga H, Nagase S, Aoki D, Coleman RL, Nishimura Y, Ratajczak CK, Hashiba H, Xiong H, Katsumata N, Enomoto T, Okamoto A. Mizuno M, et al. Int J Clin Oncol. 2023 Jan;28(1):163-174. doi: 10.1007/s10147-022-02258-x. Epub 2022 Dec 19. Int J Clin Oncol. 2023. PMID: 36534262 Free PMC article. Clinical Trial.
BACKGROUND: The phase 3 VELIA trial evaluated veliparib with carboplatin/paclitaxel and as maintenance in patients with high-grade serous ovarian carcinoma. ...
BACKGROUND: The phase 3 VELIA trial evaluated veliparib with carboplatin/paclitaxel and as maintenance in patients with high-grade se …
Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
DiSilvestro P, Colombo N, Harter P, González-Martín A, Ray-Coquard I, Coleman RL. DiSilvestro P, et al. Cancers (Basel). 2021 Nov 17;13(22):5756. doi: 10.3390/cancers13225756. Cancers (Basel). 2021. PMID: 34830911 Free PMC article. Review.
Here, we review efficacy and safety results from four recent Phase III trials in newly diagnosed EOC: SOLO1 (olaparib), PAOLA-1 (olaparib in combination with bevacizumab), PRIMA (niraparib), and VELIA (veliparib). The implications of these data for current clinical practic …
Here, we review efficacy and safety results from four recent Phase III trials in newly diagnosed EOC: SOLO1 (olaparib), PAOLA-1 (olaparib in …
Discovery of small molecules that target a tertiary-structured RNA.
Menichelli E, Lam BJ, Wang Y, Wang VS, Shaffer J, Tjhung KF, Bursulaya B, Nguyen TN, Vo T, Alper PB, McAllister CS, Jones DH, Spraggon G, Michellys PY, Joslin J, Joyce GF, Rogers J. Menichelli E, et al. Proc Natl Acad Sci U S A. 2022 Nov 29;119(48):e2213117119. doi: 10.1073/pnas.2213117119. Epub 2022 Nov 21. Proc Natl Acad Sci U S A. 2022. PMID: 36413497 Free PMC article.
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion.
Banerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A, Ray-Coquard I. Banerjee S, et al. ESMO Open. 2020 Nov;5(6):e001110. doi: 10.1136/esmoopen-2020-001110. ESMO Open. 2020. PMID: 33310779 Free PMC article. Review.
Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with BRCA1/2 mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib …
Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond p …
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M, Coleman RL, Westin SN. Onstad M, et al. Drugs. 2020 Oct;80(15):1525-1535. doi: 10.1007/s40265-020-01382-0. Drugs. 2020. PMID: 32852746 Free PMC article. Review.
In this article, we review the results of four recently published Phase III randomised controlled trials evaluating the use of PARP inhibitors in the primary treatment of ovarian cancer (SOLO1, PRIMA, PAOLA-1, and VELIA). Collectively, the studies suggest that PARP mainten …
In this article, we review the results of four recently published Phase III randomised controlled trials evaluating the use of PARP inhibito …
18 results